Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:KYMR NASDAQ:NUVL NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.83$13.93$8.50▼$20.76$2.05B2.161.63 million shs1.56 million shsKYMRKymera Therapeutics$82.21$83.58$28.06▼$103.00$6.76B2.06491,524 shs468,276 shsNUVLNuvalent$102.30$102.13$70.25▼$113.01$8.08B1.15562,921 shs798,462 shsPCVXVaxcyte$52.39$57.50$29.08▼$65.00$7.57B1.31.47 million shs1.29 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-7.10%-11.33%-20.01%+41.77%KYMRKymera Therapeutics0.00%-4.50%-6.27%-0.16%+171.77%NUVLNuvalent0.00%-2.83%-4.93%+1.47%+39.53%PCVXVaxcyte0.00%-1.17%-15.97%-3.16%+64.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.83$13.93$8.50▼$20.76$2.05B2.161.63 million shs1.56 million shsKYMRKymera Therapeutics$82.21$83.58$28.06▼$103.00$6.76B2.06491,524 shs468,276 shsNUVLNuvalent$102.30$102.13$70.25▼$113.01$8.08B1.15562,921 shs798,462 shsPCVXVaxcyte$52.39$57.50$29.08▼$65.00$7.57B1.31.47 million shs1.29 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-7.10%-11.33%-20.01%+41.77%KYMRKymera Therapeutics0.00%-4.50%-6.27%-0.16%+171.77%NUVLNuvalent0.00%-2.83%-4.93%+1.47%+39.53%PCVXVaxcyte0.00%-1.17%-15.97%-3.16%+64.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$19.5752.54% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1043.65% UpsideNUVLNuvalent 2.88Moderate Buy$137.2534.16% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0064.15% UpsideCurrent Analyst Ratings BreakdownLatest ADPT, NUVL, PCVX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026ADPTAdaptive Biotechnologies Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$21.00 ➝ $18.005/6/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $21.005/6/2026ADPTAdaptive Biotechnologies JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $19.005/6/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NUVLNuvalent HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$155.004/20/2026ADPTAdaptive Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M7.41N/AN/A$1.47 per share8.73KYMRKymera Therapeutics$39.21M172.47N/AN/A$19.42 per share4.23NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/ANUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)Latest ADPT, NUVL, PCVX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22KYMRKymera TherapeuticsN/A10.8110.81NUVLNuvalentN/A16.1416.14PCVXVaxcyteN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%KYMRKymera TherapeuticsN/ANUVLNuvalent97.26%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%KYMRKymera Therapeutics15.98%NUVLNuvalent5.02%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePCVXVaxcyte160144.40 million139.92 millionOptionableADPT, NUVL, PCVX, and KYMR HeadlinesRecent News About These Companiesabrdn Healthcare Investors Q1 2026 CommentaryMay 15 at 1:58 PM | seekingalpha.comVaxcyte Target of Unusually Large Options Trading (NASDAQ:PCVX)May 13, 2026 | americanbankingnews.comVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comVaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund DMay 11, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVXMay 10, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Misses Estimates By $0.56 EPSMay 6, 2026 | marketbeat.comVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comVaxcyte, Inc. $PCVX Shares Purchased by UBS Group AGMay 6, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Down 6.8% - What's Next?May 5, 2026 | marketbeat.comVanguard Group Inc. Sells 126,467 Shares of Vaxcyte, Inc. $PCVXMay 5, 2026 | marketbeat.comJennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVXMay 2, 2026 | marketbeat.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.comVaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in StockMay 1, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVXMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVXApril 30, 2026 | marketbeat.comVaxcyte (PCVX) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Rating Lowered to Strong Sell at Wall Street ZenApril 28, 2026 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comVaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street ZenApril 20, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADPT, NUVL, PCVX, and KYMR Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.83 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$12.76 -0.07 (-0.58%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Kymera Therapeutics NASDAQ:KYMR$82.21 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$82.25 +0.04 (+0.05%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nuvalent NASDAQ:NUVL$102.30 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$102.85 +0.55 (+0.54%) As of 06:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Vaxcyte NASDAQ:PCVX$52.39 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$52.12 -0.27 (-0.52%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
